# US 2013/0156771 A1 · Fdf03 antibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0156771 A1
- Document ID: US20130156771A1
- Status: Published application
- Kind: A1
- Application number: 13/767,702
- Filed: 2013-02-14
- Published: 2013-06-20
- Earliest claimed: 2007-12-20
- Assignees: Merck Sharp & Dohme Corp.
- Inventors: Michael E. Bigler; Drake M. LaFace; Kalyan Pande; Joseph H. Phillips
- Web page: https://patentgrep.com/patent/US20130156771A1

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 16/2896: {against molecules with a "CD"-designation, not provided for elsewhere}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/31: multispecific
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2317/75: Agonist effect on antigen
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to methods for identifying and using modulators of FDF03 biological activity in vitro and in vivo that are useful in the treatment of cancer.

## Claims

### Claim 1

A method for inhibiting tumor growth in a subject, comprising administering to a subject in need thereof an agent that stimulates or enhances FDF03 inhibitory receptor biological activity.

### Claim 2 (depends on 1)

The method of claim 1, wherein the agent is an agonist or partial-agonist antibody or antibody fragment thereof specific for the FDF03 inhibitory receptor.

### Claim 3 (depends on 2)

The method of claim 2, wherein the antibody is a humanized, fully human or chimeric antibody.

### Claim 4 (depends on 1)

The method of claim 1, wherein the tumor is a primary or a metastatic tumor.

### Claim 5 (depends on 1)

The method of claim 1, wherein the subject is a human.

### Claim 6

A method for reducing metastatic burden in a subject comprising administering to a subject in need thereof an agent that stimulates or enhances FDF03 inhibitory receptor biological activity.

### Claim 7 (depends on 6)

The method of claim 6, wherein the agent is an agonist or partial-agonist antibody, or antibody fragment thereof specific for the FDF03 inhibitory receptor.

### Claim 8 (depends on 7)

The method of claim 7, wherein the antibody is a humanized, fully human or chimeric antibody.

### Claim 9 (depends on 6)

The method of claim 6, wherein the subject is a human.

### Claim 10

A method for inhibiting tumor growth in a subject, comprising administering to a subject in need thereof an agent that binds to an FDF03 inhibiting receptor and an FDF03 activating receptor.

### Claim 11 (depends on 10)

The method of claim 10, wherein the agent is a bispecific antibody or antibody fragment thereof that binds to the FDF03 inhibitory receptor and the FDF03 activating receptor.

### Claim 12 (depends on 11)

The method of claim 11, wherein the antibody is a humanized, fully human or chimeric antibody.

### Claim 13 (depends on 10)

The method of claim 10, wherein the tumor is a primary or a metastatic tumor.

### Claim 14 (depends on 10)

The method of claim 10, wherein the subject is a human

### Claim 15

A method for reducing metastatic burden, comprising administering to a subject in need thereof an agent that binds to an FDF03 inhibiting receptor and an FDF03 activating receptor.

### Claim 16 (depends on 15)

The method of claim 15, wherein the agent is a bispecific antibody or antibody fragment thereof that binds to the FDF03 inhibiting receptor and the FDF03 activating receptor.

### Claim 17 (depends on 16)

The method of claim 16, wherein the antibody is a humanized, fully human or chimeric antibody.

### Claim 18 (depends on 15)

The method of claim 15, wherein the subject is a human.